Cancer drug development using glucose metabolism radiopharmaceuticals.

Source:http://linkedlifedata.com/resource/pubmed/id/19275662

Download in:

View as

General Info

Authors

Chen Y, Sun YY

Affiliation

Department of Nuclear Medicine, Affiliated Hospital, Luzhou Medical College, Luzhou, Sichuan, China.

Abstract

Imaging of glucose metabolism has resulted in significant improvements in staging and follow-up in oncology. (18)F-FDG PET has become a routine clinical test for most solid tumours. Several radionuclide-labeled derivatives of deoxyglucose that have shown that glucose metabolic imaging may be a useful tool for improving tumour staging, restaging, and monitoring of tumour response to therapy.

PMID
19275662

Publication types

Research Support, Non-U.S. Gov't